Trial
NCT04181762
Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Lupus Nephritis
Intervention
secukinumab
Why stopped
Study terminated by sponsor due to futility analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-16